Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Professor Tim Spector has issued an urgent warning to people who may wish to take Ozempic "without a medical need". Ozempic ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

If you're one of the 13% of American adults who has taken a GLP-1 drug for weight loss, you may know that while fat seemingly ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal.

Oprah Winfrey opens up on her podcast about her weight-loss journey with anti-obesity GLP-1 medications while chatting with doctors and guests. Plus, the media icon shares how her opinion of "thin ...

With the recent surge in popularity of weight loss drugs like Ozempic, altogether called GLP-1s, there has been renewed scientific interest in understanding how our bodies regulate muscle growth.

More thyroid cancers were detected soon after starting a GLP-1 receptor agonist than other diabetes drugs, a secondary analysis of a target trial emulation of a comparative effectiveness study found.